Quantcast
Home > Quotes > LQDA
LQDA

Liquidia Technologies, Inc. Common Stock (LQDA) Quote & Summary Data

$5.17
*  
0.49
8.66%
Get LQDA Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading LQDA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
40
Today's High / Low
$ 5.695 / $ 5.12
Share Volume
124,139
50 Day Avg. Daily Volume
81,200
Previous Close
$ 5.66
52 Week High / Low
$ 38.46 / $ 4.94
Market Cap
96,386,595
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
124,139
50 Day Avg. Daily Volume:
81,200

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.65

Trading Range

The current last sale of $5.17 is 4.66% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.695 $ 38.46
 Low: $ 5.12 $ 4.94

Company Description (as filed with the SEC)

We are a late­stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. We are currently focused on the development of two product candidates for which we hold worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension, or PAH, and LIQ865 for the treatment of local post­operative pain. Our lead product candidate, LIQ861, is being evaluated in an open­label Phase 3 clinical trial. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep­lung delivery and achieving higher dose levels than current inhaled therapies.  ... More ...  



Risk Grade

Where does LQDA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.61
Open Date:
Aug. 23, 2019
Close Price:
$ 5.17
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info